Clinical experience on EGFR tyrosine kinase inhibitor in non-small cell lung cancer, compassionate programme in Czech Republic

被引：0
|
作者：
Pesek, M.
Skrickova, J.
Kolek, V.
Zatloukal, P.
Petruzelka, L.
Svobodnik, A.
机构：
[1] Fac Med, Dept TB & Pulm Dis, Plzen, Czech Republic
[2] Fac Med, Dept TB & Pulm Dis, Brno, Czech Republic
[3] Fac Med, Dept TB & Pulm Dis, Olomouc, Czech Republic
[4] Fac Med, Dept Pneumol & Thorac Surg, Prague 8, Czech Republic
[5] Fac Med, Dept Oncol Dis, Prague 2, Czech Republic
[6] Masaryk Univ, Ctr Biostat & Anal, Brno, Czech Republic
来源：
LUNG CANCER | 2006年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [2] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [4] CLINICAL MODES OF EGFR TYROSINE KINASE INHIBITOR FAILURE AND SUBSEQUENT MANAGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Chen, H.
    Yang, J.
    Yan, H.
    Zhang, X.
    Wu, Z.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 437 - 437
  • [5] Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
    Yang, Jin-Ji
    Chen, Hua-Jun
    Yan, Hong-Hong
    Zhang, Xu-Chao
    Zhou, Qing
    Su, Jian
    Wang, Zhen
    Xu, Chong-Rui
    Huang, Yi-Sheng
    Wang, Bin-Chao
    Yang, Xue-Ning
    Zhong, Wen-Zhao
    Nie, Qiang
    Liao, Ri-Qiang
    Jiang, Ben-Yuan
    Dong, Song
    Wu, Yi-Long
    LUNG CANCER, 2013, 79 (01) : 33 - 39
  • [6] Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Sierra, J. Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CANCER RESEARCH, 2012, 72
  • [7] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [8] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [9] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [10] CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS
    Nasu, Shingo
    Takata, So
    Masuhiro, Kentaro
    Morita, Satomu
    Iwata, Kaori
    Ryota, Noriko
    Okada, Yukari
    Tokuoka, Yoshie
    Ueda, Yuki
    Kumode, Akinori
    Usui, Naoko
    Tanaka, Ayako
    Shiroyama, Takayuki
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    RESPIROLOGY, 2017, 22 : 114 - 114
12345